Brokerages Expect Evolent Health, Inc (EVH) to Post -$0.05 EPS
Analysts expect Evolent Health, Inc (NYSE:EVH) to post earnings per share of ($0.05) for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Evolent Health’s earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.09). Evolent Health posted earnings of ($0.18) per share during the same quarter last year, which would indicate a positive year over year growth rate of 72.2%. The firm is scheduled to announce its next earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Evolent Health will report full-year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.48) to ($0.36). For the next financial year, analysts expect that the business will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.22) to $0.15. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Evolent Health.
Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. The business had revenue of $107.90 million for the quarter, compared to analyst estimates of $104.49 million. Evolent Health had a negative return on equity of 5.27% and a negative net margin of 15.86%. The company’s revenue was up 79.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.26) EPS.
Several research firms recently commented on EVH. BidaskClub raised Evolent Health from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. Cantor Fitzgerald reissued a “buy” rating and set a $30.00 price target on shares of Evolent Health in a research report on Thursday. SunTrust Banks, Inc. reissued a “buy” rating and set a $30.00 price target on shares of Evolent Health in a research report on Wednesday, September 20th. Robert W. Baird set a $35.00 price target on Evolent Health and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, J P Morgan Chase & Co reissued a “buy” rating on shares of Evolent Health in a research report on Friday, August 18th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $28.70.
A number of hedge funds have recently bought and sold shares of the business. FMR LLC increased its holdings in Evolent Health by 117.7% during the 2nd quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock worth $250,073,000 after purchasing an additional 5,333,252 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Evolent Health by 7.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock worth $137,857,000 after purchasing an additional 379,185 shares during the last quarter. Vanguard Group Inc. increased its holdings in Evolent Health by 48.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock worth $95,566,000 after purchasing an additional 1,237,941 shares during the last quarter. Riverbridge Partners LLC purchased a new stake in Evolent Health during the 2nd quarter worth approximately $58,878,000. Finally, Blair William & Co. IL increased its holdings in Evolent Health by 31.4% during the 2nd quarter. Blair William & Co. IL now owns 2,185,695 shares of the technology company’s stock worth $55,407,000 after purchasing an additional 522,874 shares during the last quarter. Institutional investors own 89.64% of the company’s stock.
Evolent Health (NYSE:EVH) opened at $13.25 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.89 and a current ratio of 1.89. Evolent Health has a 52 week low of $13.20 and a 52 week high of $27.50.
COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/05/brokerages-expect-evolent-health-inc-evh-to-post-0-05-eps.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.